title: Sperm quality of subfertile males before and after treatment with human follicle-stimulating hormone.
abstract: OBJECTIVE
  To assess the potential of short-term systemic administration of FSH for improving sperm quality, including ultrastructure, in teratozoospermic patients having normal endocrine profiles.
  
  
  METHODS
  Semen parameters were assessed prospectively using light microscopy (LM), biochemical analysis, and quantitative ultramorphological analyses within 2 months before FSH administration and within 5 days after the end of treatment.
  
  
  METHODS
  Samples were collected from patients who were referred to the male fertility clinic at Bar-Ilan University.
  
  
  METHODS
  Thirty-one patients with teratozoospermia who exhibited normal hormonal profiles and who failed to fertilize their wives in at least two previous IVF attempts (n = 17) or who had wives with apparent normal fertility unable to conceive for > or = 5 years (n = 14) were classified as subfertile. One hundred one males with no previous history of infertility, whose wives conceived after < or = 12 months of pregnancy expectation, served as the control group.
  
  
  METHODS
  Treatment was 75 IU FSH administered daily for 30 days.
  
  
  METHODS
  Pretreatment and post-treatment sperm evaluation of basic and quantitative ultramorphological analyses parameters. The hypothesis was FSH treatment may improve spermatid morphogenesis by its multiple actions on the Sertoli-gamete cell compartment without interfering with the testicular hormonogenic function.
  
  
  RESULTS
  A significant improvement in agenesis of the acrosome and in the amorphous heads was observed, reaching normal values after treatment with FSH. The axonema deteriorated. No significant changes were observed in basic semen analysis parameters.
  
  
  CONCLUSIONS
  Because malformations of the fine structure of the sperm head subcellular organelles seem to be prerequisites for the success of FSH treatment, ultramorphological examination of the sperm may serve as an indication for the probability of success of this treatment.
authors.affiliation: Department of Life Sciences, Bar-Ilan University, Ramat Gan, Israel.
authors.forename: B
authors.initials: B
authors.lastname: Bartoov
authors.forename: F
authors.initials: F
authors.lastname: Eltes
authors.forename: E
authors.initials: E
authors.lastname: Lunenfeld
authors.forename: D
authors.initials: D
authors.lastname: Har-Even
authors.forename: H
authors.initials: H
authors.lastname: Lederman
authors.forename: B
authors.initials: B
authors.lastname: Lunenfeld
mesh_terms: D000328:Adult; D005640:Follicle Stimulating Hormone / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007248:Infertility, Male / Q000188:drug therapy*; D008297:Male; D008854:Microscopy, Electron; D008855:Microscopy, Electron, Scanning; D015388:Organelles / Q000187:drug effects / Q000648:ultrastructure; D011446:Prospective Studies; D013094:Spermatozoa / Q000002:abnormalities / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure
chemical_list: D005640:Follicle Stimulating Hormone